Stock Report

Pfizer Limited Reports ₹204.47 Crore Net Profit for Q1 FY27; Operating Revenue Rises 8.3% YoY

Posted On : 2026-07-30 23:04:58( TIMEZONE : IST )

Pharmaceutical major Pfizer Limited has announced its unaudited financial results for the first quarter ended June 30, 2026. The company registered a 6.6% year-on-year growth in net profit, reaching ₹204.47 crore, supported by steady top-line expansion in its core operations.

Financial Performance Overview

Revenue & Income

Revenue from Operations: Stood at ₹653.17 crore for the quarter ended June 30, 2026, marking an 8.3% increase compared to ₹603.05 crore recorded in the corresponding quarter of the previous fiscal year (Q1 FY26). Sequentially, operational revenue grew 3.8% from ₹629.23 crore in Q4 FY26.

Other Income: Came in at ₹44.84 crore, compared to ₹40.72 crore in the previous quarter and ₹67.17 crore in Q1 FY26.

Total Income: Totaled ₹698.01 crore for Q1 FY27, up from ₹669.95 crore in the sequential quarter ended March 31, 2026, and ₹670.22 crore in the corresponding quarter ended June 30, 2025.

Profitability & Tax

Profit Before Tax (PBT): Reported at ₹276.68 crore for the quarter, reflecting a 6.6% increase compared to ₹259.53 crore in Q1 FY26 and up from ₹259.78 crore (before exceptional items) in Q4 FY26. No exceptional items were recorded for Q1 FY27.

Net Profit After Tax (PAT): Reached ₹204.47 crore, up from ₹191.75 crore in the same period last year and ₹199.82 crore in the preceding quarter.

Total Tax Expense: Stood at ₹72.21 crore, comprising ₹70.93 crore in current tax and ₹1.28 crore in deferred tax.

Total Comprehensive Income: Net of taxes, total comprehensive income stood at ₹203.93 crore, after accounting for negative other comprehensive income of ₹0.54 crore.

Earnings Per Share (EPS): Basic and diluted EPS for the quarter came in at ₹44.69 per share (face value ₹10), compared to ₹41.91 in Q1 FY26 and ₹43.68 in Q4 FY26.

Cost Breakdown

Total expenses for the quarter ended June 30, 2026, stood at ₹421.33 crore, compared to ₹410.69 crore in Q1 FY26 and ₹410.17 crore in Q4 FY26.

Key expenditure lines for the quarter included:

Purchases of Stock-in-Trade: ₹182.89 crore (vs ₹124.28 crore in Q1 FY26)

Cost of Materials Consumed: ₹105.02 crore (vs ₹88.69 crore in Q1 FY26)

Other Expenses: ₹83.42 crore (vs ₹85.98 crore in Q1 FY26)

Employee Benefits Expense: ₹82.08 crore (vs ₹95.82 crore in Q1 FY26)

Depreciation and Amortization: ₹14.26 crore (vs ₹14.41 crore in Q1 FY26)

Finance Costs: ₹1.46 crore (vs ₹3.25 crore in Q1 FY26)

Changes in Inventory (Finished Goods, WIP & Stock-in-Trade): Credit of ₹(47.80) crore (vs a credit of ₹(1.74) crore in Q1 FY26)

Capital Base

As of June 30, 2026, Pfizer Limited maintained a paid-up equity share capital of ₹45.75 crore, comprising equity shares with a face value of ₹10 each, remaining unchanged across all reported periods.

Shares of Pfizer Limited was last trading in BSE at Rs. 4799.05 as compared to the previous close of Rs. 4754.75. The total number of shares traded during the day was 429 in over 154 trades.

The stock hit an intraday high of Rs. 4811.00 and intraday low of 4737.80. The net turnover during the day was Rs. 2051992.00.